Search research articles
Contact Us
Filters
Showing results (481-490 of 512) with videos related to
Page
of 52
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer
Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Cancer Discovery
|
June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
William J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
Mariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Cancer Discovery
|
January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
François-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Clinical Lung Cancer
|
December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
Mariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Solange Peters, Sarah Danson, Baktiar Hasan, et al.
Radiology
|
November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases
Lama Dawi, Younes Belkouchi, Littisha Lawrance, et al.
Nature Medicine
|
February 4, 2022
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Page
of 52
Search research articles
Search
Showing results (481-490 of 512) with videos related to
Sort By:
Page
of 52
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2026
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer
Benjamin Besse, Vivek Subbiah, Giuseppe Curigliano, et al.
Cancer Discovery
|
June 22, 2026
Targeting KRAS codon 13 mutations using direct combination approaches in non-small cell lung cancer
William J McDaid, Helen Adderley, Paolo D d'Arienzo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 21, 2022
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
Mariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Cancer Discovery
|
January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma
François-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Clinical Lung Cancer
|
December 17, 2023
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
Mariona Riudavets, Edouard Auclin, Miguel Mosteiro, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 23, 2020
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
Solange Peters, Sarah Danson, Baktiar Hasan, et al.
Radiology
|
November 26, 2024
Liquid Biopsy versus CT: Comparison of Tumor Burden Quantification in 1065 Patients with Metastases
Lama Dawi, Younes Belkouchi, Littisha Lawrance, et al.
Nature Medicine
|
February 4, 2022
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 10, 2019
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report
Anne-Marie C Dingemans, Lizza E L Hendriks, Thierry Berghmans, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2019
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, et al.
Page
of 52